HomeCompareGBIO vs VIG

GBIO vs VIG: Dividend Comparison 2026

GBIO yields 37.45% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBIO wins by $169.3K in total portfolio value
10 years
GBIO
GBIO
● Live price
37.45%
Share price
$5.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$201.6K
Annual income
$32,248.55
Full GBIO calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — GBIO vs VIG

📍 GBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBIOVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBIO + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBIO pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBIO
Annual income on $10K today (after 15% tax)
$3,183.52/yr
After 10yr DRIP, annual income (after tax)
$27,411.27/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, GBIO beats the other by $27,258.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBIO + VIG for your $10,000?

GBIO: 50%VIG: 50%
100% VIG50/50100% GBIO
Portfolio after 10yr
$117.0K
Annual income
$16,213.85/yr
Blended yield
13.86%
📊

Analyst Conviction Gap

Where Wall Street is split right now

GBIO
No analyst data
Price Target
$5.25
-1.7% upside vs current
Range: $5.00 — $5.50
Altman Z
-9.1
Piotroski
1/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBIO buys
0
VIG buys
0
No recent congressional trades found for GBIO or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBIOVIG
Forward yield37.45%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$201.6K$32.4K
Annual income after 10y$32,248.55$179.15
Total dividends collected$148.7K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GBIO vs VIG ($10,000, DRIP)

YearGBIO PortfolioGBIO Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$14,445$3,745.32$11,304$163.92+$3.1KGBIO
2$20,513$5,056.29$12,759$166.33+$7.8KGBIO
3$28,659$6,710.36$14,382$168.52+$14.3KGBIO
4$39,427$8,761.91$16,192$170.52+$23.2KGBIO
5$53,452$11,265.44$18,210$172.34+$35.2KGBIO
6$71,468$14,273.72$20,460$173.98+$51.0KGBIO
7$94,307$17,835.96$22,968$175.48+$71.3KGBIO
8$122,904$21,996.02$25,763$176.83+$97.1KGBIO
9$158,298$26,790.73$28,878$178.05+$129.4KGBIO
10$201,627$32,248.55$32,350$179.15+$169.3KGBIO

GBIO vs VIG: Complete Analysis 2026

GBIOStock

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Full GBIO Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this GBIO vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBIO vs SCHDGBIO vs JEPIGBIO vs OGBIO vs KOGBIO vs MAINGBIO vs DGROGBIO vs NOBLGBIO vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.